Trial Search Results

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific gene profile involving the ALK gene after failure of one previous chemotherapy regimen that included one platinum drug.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Pfizer

Intervention(s):

  • Drug: PF-02341066
  • Drug: Pemetrexed
  • Drug: Docetaxel

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - histologically or cytologically proven diagnosis of non-small cell lung cancer

   - positive for the ALK fusion gene (test provided by a central laboratory)

   - must have had disease progression after only one prior chemotherapy and that regimen
   but must have included one platinum drug

   - tumors must be measurable

Exclusion Criteria:

   - prior treatment with PF-02341066

   - current treatment in another clinical trial

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
650-498-7061
Not Recruiting